BlackRock Discloses Passive Stake in Xeris Biopharma
Ticker: XERS · Form: SC 13G · Filed: Jan 26, 2024 · CIK: 1867096
| Field | Detail |
|---|---|
| Company | Xeris Biopharma Holdings, Inc. (XERS) |
| Form Type | SC 13G |
| Filed Date | Jan 26, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, passive-investment, SC-13G
TL;DR
**BlackRock owns a piece of Xeris Biopharma, but they're just holding, not shaking things up.**
AI Summary
BlackRock Inc., a major investment firm, reported on January 26, 2024, that it holds a significant stake in Xeris Biopharma Holdings, Inc. as of December 31, 2023. This filing indicates BlackRock's passive ownership, meaning they are not trying to influence company management. For investors, this signals that a large, institutional investor sees value in Xeris Biopharma, potentially lending credibility to the stock.
Why It Matters
This filing shows that a major institutional investor, BlackRock, has a significant, passive stake in Xeris Biopharma, which can be a vote of confidence for current and prospective shareholders.
Risk Assessment
Risk Level: low — This filing indicates a passive investment by a large institution, which generally doesn't introduce new risks to the company.
Analyst Insight
An investor might view BlackRock's passive stake as a positive signal, suggesting institutional confidence in Xeris Biopharma, but should still conduct their own due diligence on the company's fundamentals.
Key Players & Entities
- BlackRock Inc. (company) — the reporting person and institutional investor
- Xeris Biopharma Holdings, Inc. (company) — the subject company in which BlackRock holds shares
- December 31, 2023 (date) — the date of the event requiring the filing
- January 26, 2024 (date) — the filing date of the SC 13G
Forward-Looking Statements
- BlackRock will maintain a passive investment in Xeris Biopharma Holdings, Inc. for the foreseeable future. (BlackRock Inc.) — high confidence, target: 2025-01-26
FAQ
What type of filing is this document?
This document is an SC 13G filing, specifically filed under Rule 13d-1(b) as indicated by the 'X' in the appropriate box.
Who is the reporting person in this SC 13G filing?
The reporting person is BlackRock, Inc., as stated under 'Names of reporting persons' on the cover page.
What is the name of the issuer whose securities are being reported?
The name of the issuer is Xeris Biopharma Holdings, Inc., as listed under 'Name of Issuer'.
What is the CUSIP number for the securities mentioned in this filing?
The CUSIP number for the Common Stock of Xeris Biopharma Holdings, Inc. is 98422E103, as specified in the filing.
What was the date of the event that required this SC 13G filing?
The date of the event which required the filing of this statement was December 31, 2023, as indicated in the filing.
Filing Details
This Form SC 13G (Form SC 13G) was filed with the SEC on January 26, 2024 regarding Xeris Biopharma Holdings, Inc. (XERS).